Cargando…

SPDR-4 SLFN11 RENDERS MEDULLOBLASTOMA SENSITIVE TO DNA DAMAGE CHEMOTHERAPIES

BACKGROUND: Intensive chemotherapeutic regimens with craniospinal irradiation have greatly improved survival in medulloblastoma patients. However, survival markedly differs among molecular subgroups and their biomarkers are unknown. Through unbiased screening, we found Schlafen family member 11 (SLF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakata, Satoshi, Natsumeda, Manabu, Murai, Junko, Okada, Masayasu, Fujii, Yukihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719350/ http://dx.doi.org/10.1093/noajnl/vdac167.008

Ejemplares similares

SLFN11’s surveillance role in protein homeostasis
por: Murai, Yasuhisa, et al.
Publicado: (2022)

ML-11 DETECTION OF MYD88 MUTATIONS FROM CELL FREE DNA AIDS IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM LYMPHOMAS
por: Natsumeda, Manabu, et al.
Publicado: (2019)

SPDR-2 DEVELOPMENT OF A NOVEL THERAPEUTIC STRATEGY AGAINST MEDULLOBLASTOMA TARGETING MYC
por: Ito, Hiroshi, et al.
Publicado: (2022)

Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
por: Murai, Junko, et al.
Publicado: (2016)

MBRS-32. TOPOISOMERASE II β INDUCES NEURONAL, BUT NOT GLIAL, DIFFERENTIATION IN MEDULLOBLASTOMA
por: Miyahara, Hiroaki, et al.
Publicado: (2020)

Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
por: Alvi, Erin, et al.
Publicado: (2023)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Mechanistic understanding of human SLFN11
por: Metzner, Felix J., et al.
Publicado: (2022)

GEN-7 Liquid biopsy in brain tumor patients -The present and future-
por: Natsumeda, Manabu, et al.
Publicado: (2021)

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer
por: Ballestrero, Alberto, et al.
Publicado: (2017)

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer
por: Raynaud, Christophe Michel, et al.
Publicado: (2023)

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
por: Jo, Ukhyun, et al.
Publicado: (2021)

The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
por: Coleman, Niamh, et al.
Publicado: (2020)

Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development
por: Moribe, Fumiya, et al.
Publicado: (2021)

MBRS-06. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA
por: Natsumeda, Manabu, et al.
Publicado: (2020)

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
por: Willis, Sophie E., et al.
Publicado: (2021)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

SPDR-2 Histopathological investigation of the oligodendroglial tumors resected following alkylating agent chemotherapy
por: Masato, Nakaya, et al.
Publicado: (2021)

Advantages of Dose-Dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution
por: Aoki, Hiroshi, et al.
Publicado: (2013)

COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA
por: Tsukamoto, Yoshihiro, et al.
Publicado: (2019)

ACT-05 Present and future of precision-based medicine using cancer genome panels
por: Natsumeda, Manabu, et al.
Publicado: (2020)

ET-6 EFFICACY OF NEAR-INFRARED PHOTOIMMUNOTHERAPY TARGETING PODOPLANIN IN MALIGNANT GLIOMAS
por: Natsumeda, Manabu, et al.
Publicado: (2022)

Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate—Case Report
por: Mouri, Yoshihiro, et al.
Publicado: (2022)

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
por: Shee, Kevin, et al.
Publicado: (2019)

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
por: Mezzadra, Riccardo, et al.
Publicado: (2019)

DNA damage-Induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
por: Li, Manqing, et al.
Publicado: (2018)

Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma
por: Zoppoli, Gabriele, et al.
Publicado: (2015)

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase
por: Garvie, Colin W., et al.
Publicado: (2021)

STMO-16 The usability of Detailed pre-operative 3D simulation image for Tumor Resection of High grade glioma
por: Tsukamoto, Yoshihiro, et al.
Publicado: (2021)

EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma
por: NOZAWA, Takanori, et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Transcriptomic analysis of the stationary phase response regulator SpdR in Caulobacter crescentus
por: da Silva, Carolina A. P. T., et al.
Publicado: (2016)

Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas
por: On, Jotaro, et al.
Publicado: (2021)

Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide
por: Eda, Takeyoshi, et al.
Publicado: (2022)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
por: Winkler, Claudia, et al.
Publicado: (2021)

Synchronized multiple regression of diagnostic radiation-induced rather than spontaneous: disseminated primary intracranial germinoma in a woman: a case report
por: Yoneoka, Yuichiro, et al.
Publicado: (2011)

SLFN14 gene mutations associated with bleeding
por: Stapley, Rachel J., et al.
Publicado: (2019)

SPDR-05 PARP INHIBITORS RESTORE TEMOZOLOMIDE SENSITIVITY IN MSH6-DEFICIENT TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELLS
por: Higuchi, Fumi, et al.
Publicado: (2019)

SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
por: Winkler, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_78547mklvg9st70e0stpcjr0le